Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial (Q46847543)

25 December 2017

title

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial (English)

1 reference

25 December 2017

1 reference

1 reference

1 reference

3

Jack Cuzick

1 reference

25 December 2017

Aman U Buzdar

4

object named as

Aman Buzdar

1 reference

25 December 2017

author name string

Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group

1

1 reference

25 December 2017

John F Forbes

2

1 reference

25 December 2017

Anthony Howell

5

1 reference

25 December 2017

Jeffrey S Tobias

6

1 reference

25 December 2017

Michael Baum

7

1 reference

25 December 2017

publication date

1 January 2008

1 reference

25 December 2017

Lancet Oncology Commission

published in

1 reference

25 December 2017

volume

9

1 reference

25 December 2017

page(s)

45-53

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

Global cancer statistics, 2002

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Overview of the main outcomes in breast-cancer prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Meta-analysis of vascular and neoplastic events associated with tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Uterine sarcoma associated with tamoxifen use.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970385-6

7 January 2021

10.1016/S1470-2045(07)70385-6

Identifiers

DOI

1 reference

25 December 2017

release_zm2yh36onnfjzfp4j4farbhoqy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zm2yh36onnfjzfp4j4farbhoqy

24 November 2022

mapped directly with Wikidata item

PubMed ID

18083636

1 reference

25 December 2017